Composition for treatment of pathogens that are resistant to tetracyclines

US9682079B2 · kind B2 · utility

Assignee

• BIOVERSYS AG · CH

Inventors

• Peter Schneider · Königstein, DE
• Rainer RIEDL · Frauenfeld, CH
• Marcel Tigges · Reinach, CH
• Marc Gitzinger · Laufenburg, CH
• Michel PIEREN · Binningen, CH
• Assaf Levi · Basel, CH
• Mark Sephton · Cambridge, GB
• Birgit SCHELLHORN · Henstedt-Ulzburg, DE
• Patrik Zueger · Adliswil, CH
• Michael Brand · Staufen, CH
• Daniel Gygax · Himmelried, CH
• Peter Spies · Zwingen, CH

Key dates

• Filing date: Feb 3, 2014
• Grant date: Jun 20, 2017
• Expiry date: Feb 3, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.